Nicox Announces Positive Topline Results From Phase 2 Dolomites Trial for Glaucoma

Posted on

Nicox SA announced positive topline results from its Dolomites dose-response, US multicenter Phase 2 clinal trial of investigational NCX 470. The drug is aimed at lowering intraocular pressure (IOP) to treat ocular hypertension and open-angle glaucoma.

The trial included 433 patients and compared NCX 470 0.065% and latanoprost ophthalmic solution 0.005%.

Results showed that NCX 470 0.065% was statistically significantly better than latanoprost in a pre-specified secondary efficacy analysis. Researchers also claim it demonstrated the highest IOP reduction from baseline in a glaucoma trial (7.6 to 9.8 mmHg for NCX 470 vs. 6.3 to 8.8 mmHg for latanoprost).

Nicox SA is planning an end-of-phase 2 meeting with the FDA in the first quarter of next year. Phase 3 trials plan include comparing NCX 470 with a prostaglandin analog.

You can read more here.

Related Articles
IOP outcomes after laser trabeculoplasty in eyes with prior Kahook Dual Blade goniotomy limited
Jul 28, 2021
Hydrus microstent reduces IOP, medication burden
Jul 26, 2021
IOP, gel microstents complications leading cause of reoperation after MIGS
Jul 23, 2021